Plain-English translation of NCT07407439 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study is collecting real-world information about how palbociclib, abemaciclib, ribociclib, and dalcetrapib (medications called CDK4/6 inhibitors) work when combined with hormone therapy in patients with advanced breast cancer. Researchers want to understand which medication combinations work best for different patients and what treatment options work when cancer becomes resistant to the initial medication.
Doctors need better information about how these medications perform in everyday patients (not just in controlled research settings) and which treatments work best after cancer stops responding to this medication, so they can help future patients make the best treatment choices.
You likely qualify if…
You likely don't qualify if…
Your participation is observational, meaning you won't receive any new treatment — instead, researchers will review your existing medical records, test results, and imaging scans from your treatment at the hospital. Some patients may be asked to provide a blood or tumor sample for additional research to understand why cancer sometimes becomes resistant to the medication. This is a real-world data collection study, so there are no special study visits; it uses information from your regular cancer care.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~245 participants
Started
June 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yehui Shi, MD
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.